STING1 and Miyoshi myopathy: In summary, our study validates STING as a therapeutic target in MM and proposes novel combination treatments with bortezomib, STING agonist and an immune checkpoint inhibitor, with augmented immunotherapeutic effects and promising antitumor efficacy in vivo.